8-K: Becton, Dickinson and Company Announces Strategic Spin-Off of Biosciences and Diagnostic Solutions Business and Merger with Waters Corporation in $4 Billion Reverse Morris Trust Transaction

Becton, Dickinson and Company (BD) has entered into definitive agreements to separate its Biosciences and Diagnostic Solutions business, which will then merge with Waters Corporation in a Reverse Morris Trust transaction, resulting in BD shareholders owning 39.2% of Waters and BD receiving approximately $4 billion in cash.

Summary

• Becton, Dickinson and Company (BD) will separate its Biosciences and Diagnostic Solutions business into a new wholly-owned subsidiary, Augusta SpinCo Corporation (SpinCo).
• SpinCo will distribute approximately $4 billion in cash to BD, subject to adjustments for cash, working capital, and indebtedness.
• BD will then distribute all outstanding shares of SpinCo common stock to its shareholders on a pro-rata basis (the Spin-Off).
• Immediately following the Spin-Off, SpinCo will merge with Beta Merger Sub, Inc., a wholly-owned subsidiary of Waters Corporation, with SpinCo surviving as a wholly-owned subsidiary of Waters.
• As a result of the merger, former BD shareholders will collectively own 39.2% of the outstanding Waters common stock on a fully diluted basis.
• The transaction has been unanimously approved by the Boards of Directors of both BD and Waters.
• The definitive agreements include a Separation Agreement and an Agreement and Plan of Merger, both dated July 13, 2025.
• The transaction is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes under Sections 355(a) and 368(a)(1)(D) for the Contribution and Distribution, and Section 368(a) for the Merger.
• Waters Corporation will pay BD a termination fee of $733 million if the Merger Agreement is terminated under certain specified circumstances.

Sentiment

Score: 8

Explanation: The sentiment is highly positive as the document announces a major strategic transaction that has been unanimously approved by both company boards, is intended to be tax-free, and involves a significant cash payment to BD while giving its shareholders a substantial stake in the combined entity. The detailed planning for financing and regulatory compliance also contributes to a positive outlook, despite inherent transaction risks.

Positives

• BD will receive approximately $4 billion in cash, providing significant capital.
• BD shareholders will gain a substantial 39.2% ownership stake in Waters Corporation, allowing them to participate in the future growth of the combined entity.
• The transaction is structured as a Reverse Morris Trust, which is intended to be tax-free for U.S. federal income tax purposes for BD and its shareholders.
• The transaction has received unanimous approval from the Boards of Directors of both BD and Waters, indicating strong internal support.

Negatives

• The transaction involves complex separation and integration steps, which could lead to operational challenges.
• The cash distribution and exchange ratio are subject to adjustments based on net working capital, cash, and indebtedness, which could alter the final financial outcome.
• The transaction is subject to various closing conditions, including regulatory approvals and Waters shareholder approval, which could delay or prevent its consummation.
• Potential for a termination fee of $733 million payable by Waters to BD under certain conditions, indicating potential financial implications if the deal fails.

Risks

• One or more closing conditions, including certain regulatory approvals, may not be satisfied or waived, or a governmental entity may prohibit, delay, or refuse approval.
• The proposed transaction may not be completed on the terms or in the timeframe expected, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty of the expected financial performance of the combined company following completion of the proposed transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including synergies, due to delays or integration difficulties.
• Inability of the combined company to retain and hire key personnel.
• The occurrence of any event that could give rise to termination of the proposed transaction.
• Stockholder litigation or other litigation, settlements, or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs.
• Evolving legal, regulatory, and tax regimes could adversely impact the transaction.
• Changes in general economic and/or industry-specific conditions or volatility from tariffs.
• Actions by third parties, including government agencies, could impact the transaction.
• The anticipated tax treatment of the proposed transaction may not be obtained.
• Greater than expected difficulty in separating the SpinCo business from other BD businesses.
• Disruption of management time from ongoing business operations due to the pendency of the proposed transaction.
• Other effects of the pendency of the proposed transaction on relationships with employees, customers, suppliers, or other counterparties.

Future Outlook

The transaction is expected to be completed as promptly as practicable, with the goal of achieving a tax-free reorganization for U.S. federal income tax purposes. The combined entity aims to leverage the strengths of both businesses, though the realization of anticipated benefits and synergies is subject to various risks and integration challenges. Post-closing, BD will have a non-compete clause for its divested business for three years, with certain exceptions.

Management Comments

• The Boards of Directors of both Becton, Dickinson and Company and Waters Corporation have unanimously approved the transaction.
• The parties acknowledge that the Separation Agreement, the Merger Agreement, and other Transaction Documents represent an integrated agreement and would not have been entered into independently.

Industry Context

This transaction represents a strategic divestiture by Becton, Dickinson and Company of its Biosciences and Diagnostic Solutions business, allowing BD to potentially focus on its core medical technology segments. For Waters Corporation, this merger significantly expands its presence in the life sciences and diagnostics sectors, potentially creating a more diversified and competitive entity. The use of a Reverse Morris Trust structure highlights a common strategy for large corporations to shed non-core assets in a tax-efficient manner, while providing shareholders with continued exposure to the divested business through a new, focused public entity.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• The document mentions the risk of stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations that may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification, and liability.

Related Party Transactions

• The transaction itself is a related-party transaction involving the separation of a business segment from BD and its subsequent merger with Waters, where BD shareholders become significant owners of Waters. Intercompany accounts payable and receivable between BD and SpinCo will be settled or eliminated prior to the Distribution. Various ancillary agreements (e.g., Transition Services Agreement, Tax Matters Agreement, Employee Matters Agreement, Contract Manufacturing Agreements, Intellectual Property Matters Agreement) will govern ongoing relationships between BD and the combined Waters/SpinCo entity.

Stakeholder Impact

• **Shareholders (BD)**: Will receive approximately $4 billion in cash and a 39.2% ownership stake in Waters Corporation, allowing them to participate in the future of the combined entity and potentially benefit from a tax-free transaction.
• **Shareholders (Waters)**: Will retain 60.8% ownership of Waters, with the company expanding its business scope through the merger with BD's Biosciences and Diagnostic Solutions business.
• **Employees (SpinCo Group)**: Will transition to become employees of the combined Waters/SpinCo entity. Non-solicitation clauses are in place for senior employees for 18 months post-closing.
• **Management**: Management time may be disrupted due to the pendency of the transaction and integration efforts. New board composition for Waters will include BD-selected directors.
• **Customers & Suppliers**: Business relationships are intended to be preserved, but there is a risk of disruption due to the transaction's pendency and integration.

Next Steps

• Completion of the Separation of the Biosciences and Diagnostic Solutions Business into SpinCo.
• SpinCo to distribute $4 billion in cash to BD.
• BD to distribute SpinCo common stock to its shareholders (Spin-Off).
• SpinCo to merge with Beta Merger Sub, Inc., a Waters Corporation subsidiary.
• Obtain necessary regulatory approvals, including HSR Act expiration/termination and foreign antitrust approvals.
• Effectiveness of registration statements (Form S-4 for Waters, Form 10 for SpinCo).
• Absence of legal restraints prohibiting the transaction.
• Approval of the transaction by Waters shareholders.
• Approval of Waters common stock for listing on the NYSE.
• Receipt of a private letter ruling from the IRS regarding tax consequences.
• Receipt of tax opinions from legal counsel for both BD and Waters.
• Finalization and execution of ancillary agreements (Transition Services Agreement, Tax Matters Agreement, Employee Matters Agreement, Contract Manufacturing Agreements, Intellectual Property Matters Agreement).
• BD and Waters to cooperate in preparing and filing Securities Filings (RMT Partner Registration Statement, SpinCo Registration Statement, Proxy Statement).
• Waters to call and hold a stockholders meeting to obtain RMT Partner Stockholder Approval.
• SpinCo to take actions to authorize and issue the necessary number of shares of SpinCo Common Stock for the Distribution.
• BD and Waters to cooperate in obtaining any Tax opinions required to be filed with the SEC.

Key Dates

Keywords

Reverse Morris Trust, Spin-Off, Merger, Divestiture, Biosciences, Diagnostic Solutions, Healthcare, Life Sciences, Corporate Restructuring, SEC Filing, BDX, Waters Corporation